The distinctive mBL signature consisted of 58 genes, including several target genes of the NF-κB pathway (i.e., BCL2A1, FLIP, CD44, NFKBIA, BCL3, and STAT3) that are known to distinguish activated B-cell-like or germinal center B-cell-like lymphomas. This evidence concerns the gene NFKB1 and lymphoma.